Company: PBH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001295947-25-000039
Chunk: 12

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 2
Chunk 12
---
0 (79)(2.7)Total North American OTC Healthcare230,756 84.2 239,811 84.5 (9,055)(3.8)International OTC HealthcareAnalgesics$1,501 0.5 $1,075 0.4 426 39.6 Cough & Cold6,813 2.5 6,221 2.2 592 9.5 Women's Health5,608 2.0 6,038 2.1 (430)(7.1)Gastrointestinal17,787 6.5 18,150 6.4 (363)(2.0)Eye & Ear Care4,790 1.7 6,646 2.3 (1,856)(27.9)Dermatologicals2,904 1.1 2,215 0.8 689 31.1 Oral Care3,728 1.4 3,385 1.2 343 10.1 Other OTC227 0.1 244 0.1 (17)(7.0)Total International OTC Healthcare43,358 15.8 43,974 15.5 (616)(1.4)Total Consolidated$274,114 100.0 $283,785 100.0 $(9,671)(3.4)

Total revenues for the three months ended September 30, 2025 were $274.1 million, a decrease of $9.7 million, or 3.4%, versus the three months ended September 30, 2024.

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment decreased $9.1 million, or 3.8%, during the three months ended September 30, 2025 versus the three months ended September 30, 2024.  The $9.1 million decrease was primarily attributable to a decrease in sales in the Eye & Ear Care and Women's Health categories, partly offset by an increase in sales in the Gastrointestinal category.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment decreased $0.6 million, or 1.4%, during the three months ended September 30, 2025 versus the three months ended September 30, 2024. The $0